DZ 697b
Alternative Names: DA-697b; DZ-697bLatest Information Update: 15 May 2008
At a glance
- Originator Daiichi Sankyo Company
- Class Antiplatelets; Antithrombotics
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 13 May 2008 Discontinued - Phase-I for Thrombosis in Europe (PO)
- 13 May 2008 Discontinued - Phase-I for Thrombosis in Japan (PO)
- 13 May 2008 Discontinued - Phase-I for Thrombosis in USA (PO)